Clinical characteristics and sick leave associated with infectious mononucleosis in a real-world setting in Germany

被引:6
|
作者
Kap, Elisabeth J. [1 ]
Konrad, Marcel [2 ]
Kostev, Karel [1 ]
机构
[1] IQVIA, Frankfurt, Germany
[2] FOM Univ Appl Sci Econ & Management, Frankfurt, Germany
关键词
CHRONIC-FATIGUE-SYNDROME; PREDICTORS;
D O I
10.1111/ijcp.14690
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Infectious mononucleosis (IM), mainly caused by the Epstein-Barr virus, can result in prolonged symptoms. The objective of this study was to look at the length of sick leave, diagnosis of IM, treatment and comorbidities in a real-world setting in Germany. Methods: This retrospective, cross-sectional study used electronic medical record data from office-based practices in Germany and included patients with an initial confirmed diagnosis of IM between the 1 January 1 2016 and December 31 2018. Patients of working age (18-65 years) with statutory health insurance were included in order to look at the working population who would need a sick note for their employers in case of illness. Results: Epstein-Barr virus was the most common cause of IM in this population of 1,596 patients with an average age of 32 years. The majority of patients were women in all cohorts (similar to 60%). Although CFS, myocarditis and thrombocytopenia were not recorded frequently around the index date, the occurrence did increase during the follow-up period. Around half of patients received antibiotics. About 62% of all patients were on sick leave for an average of 20 calendar days around the time of their IM diagnosis. Only 1% were still on sick leave after 6 months. Conclusions: A small percentage of patients remained on continuous sick leave after 6 months, suggesting that the long-term effect of IM on the ability to work was minor in our cohort. However, patients could still be experiencing symptoms that influence their quality of life.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] LONG COVID: CLINICAL CHARACTERISTICS AND MANAGEMENT IN THE REAL-WORLD SETTING
    Althoff, A.
    Rasouliyan, L.
    Kumar, V
    Chang, S.
    Long, S.
    Mummert, A.
    VALUE IN HEALTH, 2023, 26 (12) : S299 - S299
  • [2] High albuminuria in CKD: prevalence and characteristics in a real-world clinical setting
    Svensson, Maria K.
    Bodegard, Johan
    Thuresson, Marcus
    Ambery, Philip
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [3] CLINICAL CHARACTERISTICS OF GENERALIZED PUSTULAR PSORIASIS FLARES IN THE REAL-WORLD SETTING
    Lavasani, L.
    Rasouliyan, L.
    Noe, M.
    Rhoads, J.
    VALUE IN HEALTH, 2023, 26 (12) : S249 - S249
  • [4] High albuminuria in CKD: prevalence and characteristics in a real-world clinical setting
    Svensson, Maria K.
    Bodegard, Johan
    Thuresson, Marcus
    Ambery, Philip
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I950 - I950
  • [5] Clinical and demographic characteristics of patients (pts) treated with vemurafenib in real-world setting
    Sadetsky, N.
    Corvino, F.
    Surinach, A.
    Goodman, G.
    MELANOMA RESEARCH, 2016, 26 : E42 - E42
  • [6] Factors associated with sick leave duration in patients suffering from major depressive disorder initiating antidepressant treatment: a real-world evidence study in Germany and Spain
    Roca, Miquel
    Bonelli, Annalisa
    Cattaneo, Agnese
    Comandini, Alessandro
    Di Dato, Giorgio
    Heiman, Franca
    Pegoraro, Valeria
    Kasper, Siegfried
    Volz, Hans-Peter
    Palao, Diego
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2023, 27 (01) : 59 - 68
  • [7] Characteristics of MS patients treated with fampridine in a real-world setting based on the NeuroTransData network in Germany
    Braune, S.
    Grimm, S.
    van Hovell, P.
    Meergans, M.
    Hyde, R.
    Bergmann, A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 316 - 317
  • [8] Performance Characteristics of Breezhaler® and Aerolizer® in the Real-World Setting
    Mathieu Molimard
    Ioannis Kottakis
    Juergen Jauernig
    Sonja Lederhilger
    Ivan Nikolaev
    Clinical Drug Investigation, 2021, 41 : 415 - 424
  • [9] Tigecycline-associated hypofibrinogenemia in a real-world setting
    Campany-Herrero, David
    Larrosa-Garcia, Maria
    Lalueza-Broto, Pilar
    Rivera-Sanchez, Lucas
    Espinosa-Pereiro, Juan
    Mestre-Torres, Jaume
    Pigrau-Serrallach, Carles
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (04) : 1184 - 1189
  • [10] Tigecycline-associated hypofibrinogenemia in a real-world setting
    David Campany-Herrero
    Maria Larrosa-Garcia
    Pilar Lalueza-Broto
    Lucas Rivera-Sánchez
    Juan Espinosa-Pereiro
    Jaume Mestre-Torres
    Carles Pigrau-Serrallach
    International Journal of Clinical Pharmacy, 2020, 42 : 1184 - 1189